teprotumumab-trbw · Horizon Therapeutics (Amgen) · updated June 2026
Tepezza, an infusion for thyroid eye disease, faces lawsuits alleging it caused permanent hearing loss and tinnitus that the label failed to adequately warn about.
This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Tepezza caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.
Plaintiffs allege the manufacturer failed to adequately warn that Tepezza (teprotumumab) can cause permanent or long-term hearing loss and tinnitus.
Tepezza's prescribing information lists hearing impairment among its warnings; plaintiffs contend the label understated the risk of permanent hearing loss.
As of mid-2026, roughly 280 cases are consolidated in MDL 3079 (Northern District of Illinois). The first bellwether (test) trial is scheduled for August 2026.